RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
Johnson & Johnson announced positive Phase 1b/2 clinical trial results for its subcutaneous therapy, RYBREVANT FASPRO, in patients with advanced head and neck cancer. The drug showed a 42% response rate, leading the company to submit a supplemental application to the FDA for approval.
Why it matters
This represents a potential advancement in treatment options for patients with aggressive, previously treated head and neck cancers where therapeutic choices are currently limited.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
The text is a straightforward summary of a corporate press release regarding clinical trial data and regulatory filings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in